GeneDx Holdings Corp Stock Price, News & Analysis

GeneDx (WGS) has published an article in the American Journal of Medical Genetics highlighting its vision for implementing AI in genomic diagnostics. The company aims to leverage its comprehensive genomic and phenotypic dataset to enhance genetic disease diagnosis through AI applications. The publication demonstrates GeneDx's strategy to address the growing demand for genetic testing as costs decrease and testing becomes standard care.

Key developments include AI systems for extracting phenotypic data and prioritizing genetic variants, working alongside genetics professionals. Following the recent acquisition of Fabric Genomics, GeneDx is positioning itself to enable decentralized testing with centralized intelligence, potentially setting new standards in genomic medicine globally.

GeneDx (WGS) has completed its acquisition of Fabric Genomics, a leader in AI-powered genomic interpretation. The strategic combination creates an integrated ecosystem for genomic diagnostics, offering both centralized and decentralized testing solutions powered by GeneDx's clinical expertise and Fabric's AI technology. Fabric Genomics will operate as an independent subsidiary of GeneDx.

The acquisition accelerates key growth opportunities including: faster diagnosis for critically ill newborns through NICU genomic testing, support for global newborn screening programs, international commercial expansion across EMEA, APAC, and LATAM regions, and new recurring revenue streams through Fabric's interpretation-as-a-service model.

GeneDx reported strong Q1 2025 financial results, with total revenues reaching $87.1 million, marking a 42% year-over-year increase. The company's core exome and genome test revenue grew impressively by 62% to $71.4 million, with test volume up 24% to 20,562 tests.

Key highlights include achieving an adjusted gross margin of 69% and adjusted net income of $7.7 million, compared to a loss in Q1 2024. The company announced plans to acquire Fabric Genomics and launched new initiatives including ultraRapid Whole Genome Sequencing and Epic Aura integration.

GeneDx raised its 2025 revenue guidance to $360-375 million and maintains its target of at least 30% growth in exome/genome volume and revenue. The company expanded its coverage to 33 states for pediatric outpatient testing and 14 states for NICU rapid genome sequencing, positioning itself for continued growth in genomic medicine.

GeneDx (WGS) has announced plans to acquire Fabric Genomics, an AI-powered genomic interpretation pioneer, in a deal worth up to $51 million. The acquisition combines GeneDx's extensive rare disease data asset with Fabric Genomics' AI platform to enable decentralized testing with centralized intelligence.

The transaction, expected to close in Q2 2025, includes $33 million in cash upon closing, with additional $18 million tied to milestone achievements. This strategic move will expand GeneDx's addressable market through multiple revenue streams:

• NICU Genomic Testing: Targeting the underserved market where less than 5% of 400,000 annual NICU admissions receive genetic testing
• Genomic Newborn Screening: Addressing a market of 3.7M U.S. births and 130M globally
• Global Commercial Expansion: Enabling local sequencing with centralized AI interpretation
• Platform Economics: Leveraging 750,000+ exomes/genomes dataset for AI development and clinical decision support

GeneDx (Nasdaq: WGS), a genomic insights company, has scheduled the release of its first quarter 2025 financial results before market opening on Wednesday, April 30, 2025. The company's management will hold a conference call at 8:30 a.m. Eastern Time on the same day to discuss the quarterly financial and operating results. Interested investors must register online to participate in the conference call. Both live and archived versions of the event will be accessible through the 'Events' section on GeneDx's investor relations website.

GeneDx (WGS) has announced a commercial expansion into Inborn Errors of Immunity (IEI), targeting nearly 500 genetic disorders affecting over 200,000 patients in the US. The company aims to improve patient outcomes through exome and genome testing solutions for inherited immunological conditions.

The expansion highlights the superiority of genomic sequencing over panel-based testing, with IEI diagnostic yields of approximately 40% compared to 29% from multi-gene panels. This approach enables faster accurate diagnoses and personalized treatment decisions, including bone marrow transplantation, gene therapy, and other therapies available for over 50% of IEI patients.

In the past 18 months, GeneDx has sequenced more than 5,000 IEI patients. The company's dataset includes over 750,000 clinical exomes and genomes enriched with IEI data, opening opportunities for biopharma partnerships in research and therapeutic development.

GeneDx (WGS), a genomic insights company, has announced the granting of 46,340 restricted stock units (RSUs) to ten newly-hired employees as employment inducement awards. The grants, effective March 15, 2025, were approved by the compensation committee under GeneDx's 2023 Equity Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest equally over a four-year period, contingent on continued employment. Each RSU represents the right to receive one share of GeneDx's Class A Common Stock upon settlement. The company specializes in rare disease diagnostics, offering exome and genome tests to enable personalized healthcare solutions.

GeneDx (WGS) has been named one of Fast Company's World's Most Innovative Companies of 2025, ranking No. 2 in the Biotech category. The company is recognized for revolutionizing whole genome sequencing (WGS) with turnaround times as fast as 48 hours.

The company is leading innovation in genomic newborn screening (gNBS) through their GUARDIAN study, the largest of its kind examining gNBS in diverse newborn populations. GeneDx's screening capabilities now cover over 450 actionable genetic conditions that traditional newborn screening methods typically miss.

With 25 years of experience, GeneDx focuses on delivering early genetic disease diagnosis and improving healthcare outcomes through genomic insights. Their approach aims to transform healthcare delivery by identifying conditions before symptoms appear, potentially reducing healthcare system burden and improving patient outcomes.

GeneDx (WGS) announced its upcoming presentations at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual Meeting, showcasing its genomic research and innovation through three platform presentations and two poster presentations.

The company will present its AI-powered gene ranker Multiscore, which prioritizes genes with positive findings in exome and genome sequences by analyzing patient clinical data. This tool aims to accelerate analysis, reduce turnaround times, and lower costs for patients.

Additionally, GeneDx will present findings from an RNA sequencing program for variant of uncertain significance (VUS) resolution, and showcase collaborations with PacBio, GUARDIAN, and Seqfirst. The research presentations include studies on HiFi sequencing applications, expanded newborn screening, and parental needs during pediatric whole genome sequencing.